MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback